CBD for Breast Cancer Primary Tumors

NCT06148038 | Recruiting Phase 1 FDA Drug

• 1 other identifier: 103565
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matching low dose placebo, or matching high dose placebo using permuted block randomization with random block sizes of 6 or 12. The time window between CBD or placebo initiation and surgery will be between 5 and 56 days.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (2)

• CBD and cell proliferation

  To determine whether oral administration of cannabidiol (CBD) causes biological changes related to cell proliferation (using Ki67 expression as a marker) in primary tumors of breast cancer patients.

  2 months

• CBD and apoptosis

  To determine whether oral administration of cannabidiol (CBD) causes biological changes related to apoptosis (using Ki67 expression as a marker) in primary tumors of breast cancer patients.

  2 months

Secondary Outcomes (2)

• Number of participants with treatment-related adverse events as assessed by CTCAE 5.0

  2 months

• GAD-7 anxiety level scoring at Pre and post CBD administration

  2 months

Study Arms (2)

CBD Oral

EXPERIMENTAL

CBD Oral 175mg or 350mg twice daily for 5-56 days

Drug: CBD Oral

Placebo control

PLACEBO COMPARATOR

Placebo control Oral twice daily for 5-56 days

Other: Control

Interventions

CBD Oral DRUG

CBD Oral 175mg or 350mg twice daily for 5 days-56 days

CBD Oral

Control OTHER

Placebo Control

Placebo control

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who are able to consent for surgery.
• Histologically confirmed invasive breast cancer (stages I, II, or III) with Ki67 proliferation rate greater than or equal to 10%.
• Women 18 years of age or older at time of consent.
• Women of child-bearing potential (WOCBP) must agree to use an approved form of birth control and to have a negative pregnancy test result before registration. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to registration:
• ANC ≥ 1.5 × 109/L
• Platelet count ≥ 100 × 109/L
• Hemoglobin ≥ 9 g/dL
• Albumin ≥ 2.5 g/dL
• Bilirubin ≤ 1.5 × the upper limit of normal (ULN)
• AST, ALT, and alkaline phosphatase ≤ 3 × ULN
• Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min on the basis of measured CrCl from a 24-hour urine collection or Cockcroft-Gault\* glomerular filtration rate estimation:
• (140-age) × (weight in kg) × (0.85 if female)
• × (serum creatinine in mg/dL)

You may not qualify if:

• Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy.
• Known allergy to sesame. Please note the study product contains sesame oil.
• South Carolina State employees or anyone whose work requires THC drug testing.
• Patients taking drugs metabolized by cytochrome p450 including warfarin, amiodarone, levothyroxine, clobazam, lamotrigine, valproate, prednisolone, hydrocortisone, clarithromycin, itraconazole, erythromycin, fluconazole, clopidogrel, rifampin, sulfamethoxazole, any opioids, and antiepileptic medications including carbamazapine, phenytoin, and valproic acid.
• Self reported routine use of recreational or medicinal marijuana products, including over-the-counter CBD oil, Marinol®, Delta-8 THC, or cannabis (defined as \> 4 times over last 30 days) or illicit drug use including opioids, cocaine, amphetamines, PCP, LSD.
• Self reported concurrent use of over-the-counter CBD oil, Marinol®, Delta-8 THC, or cannabis.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to CBD or placebo.
• Underlying history of epilepsy/ recurrent seizure disorder or unexplained seizure within past 6 months.
• Patients with uncontrolled cardiovascular disease defined by myocardial infarction, stroke, or transient ischemic attack, or need for coronary stent placement within past six months.
• Patients with a medical history of psychiatric illness or psychiatric symptoms that would prevent them from completing study procedures or would disqualify them from surgical intervention (e.g., untreated schizophrenia, bipolar disorder, or suicide ideation/attempt resulting in psychiatric hospitalization within the last 30 days).
• Women who are pregnant or breastfeeding.
• Use of blood thinners at the time of registration (warfarin, rivaroxaban, clopidogrel, and apixaban) .

Sponsors & Collaborators

• Medical University of South Carolina: lead

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

HCC Clinical Trials Office

CONTACT

843-792-9321; hcc-clinical-trials@musc.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Because the volume of CBD and matching placebo administration is different for low dose (1.75 ml) versus high dose (3.50 ml) arms, it is not possible to conduct a fully blinded trial. Patients and all study staff, including the PI interacting with participants, the technicians conducting the biologic assays, and the statisticians who will perform data analysis, will know whether a patient is assigned to low dose or high dose. However, all parties will be blind as to CBD or placebo administration until the time of database lock.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 17, 2023
• First Posted: November 28, 2023
• Study Start (Estimated): June 15, 2026
• Primary Completion (Estimated): March 25, 2028
• Study Completion (Estimated): March 25, 2029
• Last Updated: April 9, 2026

Record last verified: 2026-04

Locations

US (1)